Palbociclib was the first FDA approved CDK4/6 inhibitor and highly efficacious in the treatment of HR+/HER2- breast cancers, followed by the structurally related molecules ribociclib and abemaciclib7–11. Here, ERBB2 is linked to breast carcinoma.